Discovering, Validating & Implementing Novel Translatable Neuroinflammatory & Neurodegenerative Biomarkers

 

Thank you to our speakers, sponsors, and delegates who joined us in XXX for the summit! If you are interested in the 2025 event, please get in touch at info@hansonwade.com

Accelerating More Sensitive, Quantitative & Predictive Serological & Imaging Biomarkers to Transform Clinical Development in the CNS

With the Donanemab ADCOM hailing fluid biomarkers as a deciding factor in the unanimous decision, improved plasma ptau 217 markers and PET tracers, and α-syn self-seeding assay sensitivity and enhancing NFL utility beyond SOD-1 ALS, 2024 has opened the floodgates for biomarker innovation.

The 2nd Fluid & Imaging Biomarkers & Endpoints in Neuroscience forum united biomarker discovery scientists, imaging experts, neuroscience clinical program leads, and regulatory leaders to engage in forward-thinking discussions to meaningfully advance biomarker assessments of neurodegenerative and neuroinflammatory disease-modifying therapeutics.

October 2024, joined 50+ biomarker discovery scientists, imaging experts, neuroscience clinical program leaders, and regulatory leaders from renowned organizations like Alector, Biogen, Bristol Myers Squibb, Eli Lilly, Eisai, Pfizer, Takeda, Regeneron, and the Michael J. Fox Foundation and many more at the ultimate unique industry-focused networking opportunity to advance precision medicine in neurodegenerative and neuroinflammatory diseases.

2024 World-Class Speaker Faculty Included:

2024 Attending Companies Included:

Screenshot 2024-09-30 172748

2024 Partners:

Fluid & Imaging Biomarkers & Endpoints in Neuroscience
AlamarDropLogo_4c
Logotype_blk (4)

Other Events in the World CNS Series: